HALLE (SAALE), Germany, 13 September 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announced today […]
In an acute peritonitis model PQ912 inhibits monocyte infiltration, increases eosinophils and enhances resolvin D2, an important lipid mediator which contributes to termination of inflammatory processes […]
HALLE (SAALE), Germany, 30 August 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced its […]
Attendance at key conferences in September 2016 HALLE (SAALE), Germany, 25 August 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions […]
HALLE (SAALE), Germany, 23 August 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its results […]
Attendance at key conferences during August and September 2016 HALLE (SAALE), Germany, 16 August 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel […]
HALLE (SAALE), Germany, 12 August 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced updates […]
License and supply agreement is based on Crossbeta’s proprietary technology and supports Probiodrug’s biomarker development activities HALLE (SAALE), Germany, UTRECHT, The Netherlands, 30 June 2016 […]
Patent grants cover Probiodrug’s lead QC inhibitor PQ912, for treatment of AD and the use of QC inhibition for treatment of mild cognitive impairment (MCI) Strengthens […]
HALLE (SAALE), Germany, 27 May 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces that the […]
HALLE (SAALE), Germany, 20 May 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces that its […]
HALLE/SAALE, Germany, 12 May 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces its […]